Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2011 June;63(3) > Minerva Ginecologica 2011 June;63(3):299-304

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  NEW INSIGHTS INTO GYNECOLOGY IN 2011 

Minerva Ginecologica 2011 June;63(3):299-304

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Pharmacological profile of estrogens in oral contraception

Bitzer J.

Department of Obstetrics and Gynecology University Hospital Basel, Basel, Switzerland


PDF


The synthetic estrogen ethinylestradiol (EE)given by mouth is stable and yields satisfactory results in terms of ovulation inhibition and effects on the endometrium. It increases however the risk especially for venous thrombotic events and to a lesser degree also arterial thrombosis. Therefore research focused on diminuition of the EE dosage and the development of a different estrogen component in oral contraceptives, specifically an estrogen occurring during physiological processes in the female body. Two estrogens emerge: 17ß Estradiol is the most potent natural estrogen and it is the major estrogen secreted by the ovaries. Estetrol is a human sex steroid (15 alpha hydroxyestriol) which is only produced during pregnancy by the fetal liver. The pharmacolokinetic and pharmacodynamic properties of these estrogens are compared to those of EE (absorption, metabolization, bioavailability etc.) and the clinical profile is described as far it is known from a limited number of studies.

top of page